COMMUNIQUÉS West-GlobeNewswire

SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019
25/09/2019
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the [...]
VitalHub Corp. Announces Early Redemption Of $2,219,000 Outstanding Debentures & New Debt Financing
25/09/2019
TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSXV: VHI) (the “ Company ” or “ VitalHub ”) is pleased to announce that it has redeemed in full the $2,219,000 aggregate principal amount of outstanding [...]
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
25/09/2019
SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]
Dance Biopharm Announces Rebranding to Aerami Therapeutics Reflecting a Broadened Strategic Focus on Inhaled Therapies for Chronic Diseases
25/09/2019
Aerami is exploring inhaled therapies beyond human insulin in multiple chronic conditions Launched three new pipeline programs aimed at treatment of type 2 diabetes, hypoparathyroidism and human growth hormone [...]
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients
25/09/2019
Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m. Eastern [...]
T2 Biosystems Enters into Distribution Agreement to Expand its Innovative Rapid Diagnostic Technologies to Puerto Rico and the U.S. Virgin Islands
25/09/2019
LEXINGTON, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it [...]
Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
25/09/2019
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15 th , 2019 SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 ( [...]
Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure
25/09/2019
Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study ‘104 now proceeding to a third cohort at a dose of 90 mg NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular [...]
RTI Surgical® Showcases Advancements in Spine Portfolio and Clinical Data at NASS 2019
25/09/2019
RTI announces interim clinical outcomes on 150 patients at 6-month follow-up in the EVoluSIon study for the SImmetry® Sacroiliac Joint Fusion System showing statistically significant reductions in pain of 56% and opioid [...]
Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer
25/09/2019
Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative [...]
Microbix Presenting at Muskoka Capital Conference
25/09/2019
Meetings with Growth-Oriented Investors, September 27-29, 2019 MISSISSAUGA, Ontario, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and [...]
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria
25/09/2019
– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 – – Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: [...]
Rhythm Pharmaceuticals Provides Update on Research and Development Programs
25/09/2019
-- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,584 individuals) who have a [...]
Orchard Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa
25/09/2019
BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life- [...]
Summit Therapeutics to Host R&D Day 7 October 2019
25/09/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today [...]
Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®
25/09/2019
BEDMINSTER, N.J., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to [...]
Teleflex Announces Tenth Anniversary of GuideLiner® Catheter Product Line
25/09/2019
Company Celebrates 10 Years of the Industry's Leading Guide Extension Catheter with More Than 1 Million Units Sold Worldwide WAYNE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading [...]
Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion
25/09/2019
Press release Malmö, 25 September 2019 Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion The board of directors of Acarix AB ("Acarix" or the "Company") has [...]
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
25/09/2019
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial [...]

Pages